This E-mail is produced by AMEDEO through an unrestricted educational grant from Boehringer Ingelheim
1. AMEDEO HIV Infection
2011-01-24
If you are an expert in your field, consider writing a Flying Publisher Guide and reach out to a worldwide audience.
Pages: 75
Authors: 3-6
PDF: free
Downloads per year: 20.000-100.000
Print edition: for sale at Amazon.com
Registration to the Flying Publisher Guide Program is free until 31 December 2011. Thereafter, Flying Publisher will charge a one-time fee of 7,500 euros that covers the first and all subsequent editions. A special Amedeo grant program will help finance the fee.
75 pages, PDF
3. Free Books + 2000 Free Journals
Best regards,
Bernd Sebastian Kamps
________________ ** New articles ** _________________
1. FRANQUELIM HG, Chiantia S, Veiga AS, Santos NC, et al.
Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their
epitopes.
AIDS. 2011.
ABSTRACT available
2. DUPREZ DA, Neuhaus J, Tracy R, Kuller LH, et al.
N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events
in HIV-infected patients.
AIDS. 2011.
ABSTRACT available
3. PATON NI, Meynard JL, Pulido F, Arenas-Pinto A, et al.
Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in
HIV' in the Monotherapy Switzerland/Thailand (MOST) trial.
AIDS. 2011;25:393-4.
4. SPIEGEL PB, Mills E, Joffres MR, Anema A, et al.
The imperative to respond with appropriate and timely interventions to mass rape
in conflict-affected areas.
AIDS. 2011;25:391.
5. GHOSN J.
SENSE makes us rethink the second-generation nonnucleoside reverse transcriptase
inhibitor etravirine's place in HIV-1 treatment.
AIDS. 2011;25:383-4.
6. ROSSI D, Gaidano G.
Tracking the biological risk of coronary artery disease in HIV-infected
individuals: the case of circulating endothelial progenitor cells.
AIDS. 2011;25:379-81.
7. BAE JW, Guyer W, Grimm K, Altice FL, et al.
Medication persistence in the treatment of HIV infection: a review of the
literature and implications for future clinical care and research.
AIDS. 2011;25:279-90.
ABSTRACT available
8. SASTRI J, Campbell EM.
Recent Insights into the Mechanism and Consequences of TRIM5alpha Retroviral
Restriction.
AIDS Res Hum Retroviruses. 2011.
ABSTRACT available
9. PERSAUD D, Bedri A, Ziemniak C, Moorthy A, et al.
Slower Clearance of Nevirapine Resistant Virus in Infants Failing Extended
Nevirapine Prophylaxis for Prevention of Mother-to Child HIV-Transmission.
AIDS Res Hum Retroviruses. 2011.
ABSTRACT available
10. KAO CF, Chang SY, Hsia KT, Chang FY, et al.
Surveillance of HIV Type 1 Recent Infection and Molecular Epidemiology Among
Different Risk Behaviors Between 2007 and 2009 After the HIV Type 1 CRF07_BC
Outbreak in Taiwan.
AIDS Res Hum Retroviruses. 2011.
ABSTRACT available
11. VERONESE F, Wira CR.
2010 Workshop: Mucosal Immunity in the Male and Female Reproductive Tract and
Prevention of HIV Transmission.
AIDS Res Hum Retroviruses. 2011.
ABSTRACT available
12. NG OT, Munshaw S, Lamers SL, Chew KK, et al.
Molecular Epidemiology of HIV-1 in Singapore and Identification of Novel
CRF01_AE/B Recombinant Forms.
AIDS Res Hum Retroviruses. 2011.
ABSTRACT available
13. SPAULDING AC, Seals RM, McCallum VA, Perez SD, et al.
Prisoner Survival Inside and Outside of the Institution: Implications for
Health-Care Planning.
Am J Epidemiol. 2011.
ABSTRACT available
14. CALLEBAUT C, Stray K, Tsai L, Williams M, et al.
In Vitro Characterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of
HIV-1 Protease with Favorable Resistance Profile.
Antimicrob Agents Chemother. 2011.
ABSTRACT available
15. HRUZ PW, Yan Q, Tsai L, Koster J, et al.
GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in
cultured adipocytes or in a healthy rodent model system.
Antimicrob Agents Chemother. 2011.
ABSTRACT available
16. MAHALINGAM A, Simmons AP, Ugaonkar SR, Watson KM, et al.
Vaginal microbicide gel for the delivery of IQP-0528, a pyrimidinedione analog
with a dual mechanism of action against HIV-1.
Antimicrob Agents Chemother. 2011.
ABSTRACT available
17. JACOBELLI S, Laude H, Carlotti A, Rozenberg F, et al.
Epidermodysplasia Verruciformis in Human Immunodeficiency Virus-Infected
Patients: A Marker of Human Papillomavirus-Related Disorders Not Affected by
Antiretroviral Therapy.
Arch Dermatol. 2011.
ABSTRACT available
18. BLACKARD JT, Welge JA, Taylor LE, Mayer KH, et al.
HIV Mono-infection Is Associated With FIB-4--A Noninvasive Index of Liver
Fibrosis--in Women.
Clin Infect Dis. 2011.
ABSTRACT available
19. HUNT PW, Hatano H, Sinclair E, Lee TH, et al.
HIV-Specific CD4+ T Cells May Contribute to Viral Persistence in HIV Controllers.
Clin Infect Dis. 2011.
ABSTRACT available
20. LI L, Tan S, Lu H, Lu L, et al.
Combinations of 3-Hydroxyphthalic Anhydride-modified Ovalbumin with
Antiretroviral Drug-based Microbicide Candidates Display Synergistic and
Complementary Effects against HIV-1 Infection.
J Acquir Immune Defic Syndr. 2011.
ABSTRACT available
21. FRANCO D, Liu W, Gardiner DF, Hahn BH, et al.
CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting
dendritic cells.
J Acquir Immune Defic Syndr. 2011.
ABSTRACT available
22. WIGGILL TM, Mantina H, Willem P, Perner Y, et al.
Changing Pattern of Lymphoma Subgroups at a Tertiary Academic Complex in a High
Prevalence HIV setting - a South African Perspective.
J Acquir Immune Defic Syndr. 2011.
ABSTRACT available
23. WAHL SM, Redford M, Christensen S, Mack W, et al.
Systemic and Mucosal Differences in HIV Burden, Immune and Therapeutic Responses.
J Acquir Immune Defic Syndr. 2011.
ABSTRACT available
24. VAN ZYL GU, van Mens TE, McIlleron H, Zeier M, et al.
Low lopinavir plasma or hair concentrations explain second line protease
inhibitor failures in a resource-limited setting.
J Acquir Immune Defic Syndr. 2011.
ABSTRACT available
25. YI T, Cocohoba J, Cohen M, Anastos K, et al.
The Impact of the AIDS Drug Assistance Program (ADAP) on Use of Highly Active
Antiretroviral and Antihypertensive Therapy among HIV-Infected Women.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
26. CATTAMANCHI A, Smith R, Steingart KR, Metcalfe JZ, et al.
Interferon-gamma release assays for the diagnosis of latent tuberculosis
infection in HIV-infected individuals - A systematic review and meta-analysis.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
27. FINK VI, Shepherd BE, Cesar C, Krolewiecki A, et al.
Cancer in HIV-infected Persons from the Caribbean, Central and South America.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
28. PADIAN NS, Holmes CB, McCoy SI, Lyerla R, et al.
Implementation Science for PEPFAR.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
29. JENNESS SM, Neaigus A, Murrill CS, Wendel T, et al.
Estimated HIV Incidence Among High-Risk Heterosexuals in New York City, 2007.
J Acquir Immune Defic Syndr. 2011;56:193-7.
ABSTRACT available
30. DEPATUREAUX A, Charpentier C, Leoz M, Unal G, et al.
Impact of HIV-1 Group O Genetic Diversity on Genotypic Resistance Interpretation
by Algorithms Designed for HIV-1 Group M.
J Acquir Immune Defic Syndr. 2011;56:139-145.
ABSTRACT available
31. BOUCHAUD O, Le Moing V, Simon F, Ngo Van P, et al.
Similar Short-Term Efficacy of Antiretroviral Therapy in Patients Infected With
HIV B and Non-B Subtype Strains in France.
J Acquir Immune Defic Syndr. 2011;56:e67-e69.
32. TORO PL, Schneider KL, Carter RJ, Abrams EJ, et al.
Maternal and Infant Outcomes With Concurrent Treatment of Tuberculosis and HIV
Infection in Pregnant Women.
J Acquir Immune Defic Syndr. 2011;56:e63-6.
33. SELLIER PO, Mario N, Rami A, Andreoli A, et al.
Is Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Before Starting Sulfa
Useful In HIV-Infected Male Patients Originating From Sub-Saharan Africa?
J Acquir Immune Defic Syndr. 2011;56:e60-3.
34. REXROTH K, Hare K, Kan VL.
Rapid Oral HIV Screening: Expectations Revisited.
J Acquir Immune Defic Syndr. 2011;56:e59-60.
35. MANFREDI R.
Hyperinflation of Quoted Co-Authors in Observational and Clinical Studies,
Intercohort and Pooled Analyses, in the Field of HIV Disease. An Increasing
Worrying Phenomenon for Its Clinical Consequences and the Degeneration of the
Role of Authorship.
J Acquir Immune Defic Syndr. 2011;56:e56-8.
36. FALASCA F, Maida P, Montagna C, Antonelli L, et al.
Expression of the mRNA Levels for MDR1, MRP1, MRP4, and MRP5 IN HIV
Antiretroviral Naive Patients: Follow-up at 48 Weeks After the Beginning of
Therapy.
J Acquir Immune Defic Syndr. 2011;56:e54-6.
37. COSSARINI F, Boeri E, Canducci F, Salpietro S, et al.
Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients
With Recent Diagnosis of HIV-1 Infection.
J Acquir Immune Defic Syndr. 2011;56:e51-3.
38. MACENEANEY OJ, Connick E, Desouza CA.
Effects of HIV-1 gp120 and Protease Inhibitors on Apoptotic Susceptibility of
CD34+ Hematopoietic Progenitor Cells.
J Acquir Immune Defic Syndr. 2011;56:e49-50.
39. CARROL ED, Payton A, Payne D, Miyajima F, et al.
The IL1RN Promoter rs4251961 Correlates with IL-1 Receptor Antagonist
Concentrations in Human Infection and Is Differentially Regulated by GATA-1.
J Immunol. 2011.
ABSTRACT available
40. JIANG W, Lederman MM, Harding CV, Sieg SF, et al.
Presentation of Soluble Antigens to CD8+ T Cells by CpG
Oligodeoxynucleotide-Primed Human Naive B Cells.
J Immunol. 2011.
ABSTRACT available
41. ARMSTRONG WS, Del Rio C.
Gender, race, and geography: do they matter in primary human immunodeficiency
virus infection?
J Infect Dis. 2011;203:437-8.
42. MEDITZ AL, Mawhinney S, Allshouse A, Feser W, et al.
Sex, Race, and Geographic Region Influence Clinical Outcomes Following Primary
HIV-1 Infection.
J Infect Dis. 2011;203:442-51.
ABSTRACT available
43. GARCIA F, Climent N, Assoumou L, Gil C, et al.
A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection.
J Infect Dis. 2011;203:473-478.
ABSTRACT available
44. CORRAH TW, Goonetilleke N, Kopycinski J, Deeks SG, et al.
A REAPPRAISAL OF THE RELATIONSHIP BETWEEN THE HIV-1-PROTECTIVE SINGLE NUCLEOTIDE
POLYMORPHISM 35kb UPSTREAM OF THE HLA-C GENE AND SURFACE HLA-C EXPRESSION.
J Virol. 2011.
ABSTRACT available
45. CHAILLON A, Braibant M, Moreau T, Thenin S, et al.
The V1V2 domain and a N-linked glycosylation site in the V3 loop of the HIV-1
envelope glycoprotein modulate neutralization sensitivity to the human broadly
neutralizing antibody 2G12.
J Virol. 2011.
ABSTRACT available
46. PALERMO RE, Patterson LJ, Aicher LD, Korth MJ, et al.
GENOMIC ANALYSIS REVEALS PRE- AND POST-CHALLENGE DIFFERENCES IN A RHESUS MACAQUE
AIDS VACCINE TRIAL: INSIGHTS INTO MECHANISMS OF VACCINE EFFICACY.
J Virol. 2010.
ABSTRACT available
47. PORNILLOS O, Ganser-Pornillos BK, Yeager M.
Atomic-level modelling of the HIV capsid.
Nature. 2011;469:424-7.
ABSTRACT available
48. WAINBERG MA.
AIDS: Drugs that prevent HIV infection.
Nature. 2011;469:306-7.
49. LANOY E, Guiguet M, Bentata M, Rouveix E, et al.
Survival after neuroAIDS: Association with antiretroviral CNS
Penetration-Effectiveness score.
Neurology. 2011.
ABSTRACT available
50. OVBIAGELE B, Nath A.
Increasing incidence of ischemic stroke in patients with HIV infection.
Neurology. 2011.
ABSTRACT available
51. STRAMER SL, Wend U, Candotti D, Foster GA, et al.
Nucleic acid testing to detect HBV infection in blood donors.
N Engl J Med. 2011;364:236-47.
ABSTRACT available
52. NICOLAOU KC, Sanchini S, Sarlah D, Lu G, et al.
Organic Synthesis toward Small-Molecule Probes and Drugs Special Feature: Design,
synthesis, and biological evaluation of a biyouyanagin compound library.
Proc Natl Acad Sci U S A. 2011.
ABSTRACT available
53. THURESSON PO, Heeg B, Lescrauwaet B, Sennfalt K, et al.
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in
treatment-naive human immunodeficiency virus-1 patients in Sweden.
Scand J Infect Dis. 2011.
ABSTRACT available
54. ETCHEVERRY MF, Lum PJ, Evans JL, Sanchez E, et al.
HIV vaccine trial willingness among injection and non-injection drug users in two
urban centres, Barcelona and San Francisco.
Vaccine. 2011.
ABSTRACT available
55. NIU L, Termini JM, Kanagavelu SK, Gupta S, et al.
Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines
expressing consensus Gag antigens and conserved Gag epitopes.
Vaccine. 2011.
ABSTRACT available
56. KITCHEN SG, Shimizu S, An DS.
Stem cell-based anti-HIV gene therapy.
Virology. 2011.
ABSTRACT available
57. SSEMWANGA D, Lyagoba F, Ndembi N, Mayanja BN, et al.
Multiple HIV-1 infections with evidence of recombination in heterosexual
partnerships in a low risk Rural Clinical Cohort in Uganda.
Virology. 2011.
ABSTRACT available
58. SALGADO M, Lopez-Romero P, Callejas S, Lopez M, et al.
Characterization of host genetic expression patterns in HIV-infected individuals
with divergent disease progression.
Virology. 2011.
ABSTRACT available
59. KAULITZ D, Fiebig U, Eschricht M, Wurzbacher C, et al.
Generation of neutralising antibodies against porcine endogenous retroviruses
(PERVs).
Virology. 2011.
ABSTRACT available
60. SKASKO M, Tokarev A, Chen CC, Fischer WB, et al.
BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu:
Evidence for a post-ER mechanism of Vpu-action.
Virology. 2011.
ABSTRACT available
61. LATINOVIC O, Reitz M, Le NM, Foulke JS, et al.
CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5
infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary
cells.
Virology. 2011.
ABSTRACT available
62. DIONG C, Raboud J, Li M, Cooper C, et al.
HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against
antiretroviral-related hyperlipidaemia.
HIV Med. 2011 Jan 18. doi: 10.1111/j.1468-1293.2010.00897.
ABSTRACT available
_____________________ ** End ** ______________________
We have screened the following journals for you:
AIDS
AIDS Clin Care
AIDS Read
AIDS Res Hum Retroviruses
Am J Epidemiol
Am J Hematol
Am J Med
Ann Intern Med
Ann Neurol
Antimicrob Agents Chemother
Antivir Ther
Arch Dermatol
Arch Dis Child
Arch Intern Med
Arch Neurol
Blood
BMJ
Br J Dermatol
Br J Haematol
Cancer
Cell
Clin Infect Dis
Dermatology
Drugs
HIV Med
Immunology
Int J Cancer
Int J Dermatol
J Acquir Immune Defic Syndr
J Am Acad Dermatol
J Clin Immunol
J Clin Invest
J Clin Oncol
J Immunol
J Infect Dis
J Med Virol
J Pediatr
J Virol
JAMA
Lancet
MMWR
N Engl J Med
Nat Med
Nature
Neurology
Pediatr Infect Dis J
Pediatrics
Proc Natl Acad Sci U S A
Scand J Infect Dis
Science
Vaccine
Virology
_________________________________________________________
